Overview

Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced Dyskinesia

Status:
Completed

Trial end date:
2011-07-01

Target enrollment:

Participant gender:

Summary

This Phase IIb exploratory study is designed to determine whether AFQ056 is safe and effective and whether it can increase the therapeutic window of L-dopa in patients whose control of their Parkinson's Disease symptoms is limited by the development of dyskinesia induced by use of L-dopa.

Phase:

Phase 2

Details

Lead Sponsor:

Novartis

Treatments:

Dihydroxyphenylalanine
Levodopa